Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors purchased 2,770 call options on the company. This is an increase of 311% compared to the average volume of 674 call options.
Wall Street Analysts Forecast Growth
XENE has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, October 2nd. Royal Bank Of Canada dropped their price objective on Xenon Pharmaceuticals from $81.00 to $70.00 and set an “outperform” rating for the company in a report on Friday, September 18th. Guggenheim initiated coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 6th. They set a “buy” rating and a $73.00 price target on the stock. Wall Street Zen downgraded Xenon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 11th. Finally, JPMorgan Chase & Co. cut their price objective on Xenon Pharmaceuticals from $82.00 to $80.00 and set an “overweight” rating on the stock in a report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $71.15.
Get Our Latest Analysis on Xenon Pharmaceuticals
Insider Activity
In other news, CFO Thomas Patrick Kelly bought 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 30th. The stock was acquired at an average cost of $37.32 per share, for a total transaction of $559,800.00. Following the purchase, the chief financial officer owned 15,000 shares of the company’s stock, valued at approximately $559,800. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Christopher Kenney sold 7,068 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $60.25, for a total value of $425,847.00. Following the transaction, the insider owned 2 shares of the company’s stock, valued at $120.50. The trade was a 99.97% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.91% of the stock is owned by insiders.
Hedge Funds Weigh In On Xenon Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Xenon Pharmaceuticals by 60.2% during the third quarter. GAMMA Investing LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 312 shares during the period. Corient Private Wealth LP boosted its position in shares of Xenon Pharmaceuticals by 1.5% during the 2nd quarter. Corient Private Wealth LP now owns 28,732 shares of the biopharmaceutical company’s stock worth $1,734,000 after purchasing an additional 430 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Xenon Pharmaceuticals by 25.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,297 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 467 shares during the period. Arizona State Retirement System grew its stake in shares of Xenon Pharmaceuticals by 2.3% in the 2nd quarter. Arizona State Retirement System now owns 22,382 shares of the biopharmaceutical company’s stock valued at $1,351,000 after buying an additional 513 shares during the period. Finally, Covestor Ltd grew its stake in shares of Xenon Pharmaceuticals by 418.5% in the 3rd quarter. Covestor Ltd now owns 674 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 544 shares during the period. Institutional investors own 95.45% of the company’s stock.
Xenon Pharmaceuticals Trading Down 1.9%
NASDAQ:XENE traded down $0.72 during trading hours on Thursday, hitting $37.03. 243,523 shares of the company were exchanged, compared to its average volume of 1,385,516. The stock has a market capitalization of $3.58 billion, a price-to-earnings ratio of -7.89 and a beta of 0.11. Xenon Pharmaceuticals has a one year low of $33.38 and a one year high of $72.66. The company has a fifty day simple moving average of $39.88 and a 200 day simple moving average of $52.08.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.02. Equities research analysts predict that Xenon Pharmaceuticals will post -4.63 earnings per share for the current fiscal year.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.
See Also
- Five stocks we like better than Xenon Pharmaceuticals
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
